RecruitingNCT06839469
Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
Sponsor
Columbia University
Enrollment
106 participants
Start Date
May 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this research is (1) to identify disease specific walking-related digital biomarkers of disease severity, and (2) monitor longitudinal changes in natural environments, for extended periods of time, in DMD and SMA.
Eligibility
Min Age: 5 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with duchenne muscular dystrophy (dmd) and spinal muscular atrophy type 3. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 5 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06839469
Related Trials
Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
NCT071729711 location
Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials
NCT076747589 locations
A Remote Study Using Technology to Assess Outcomes in DMD
NCT074230261 location
Duchenne Electronic Health Record Study
NCT0760939410 locations
Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
NCT076084321 location